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Abstract
Pseudomonas aeruginosa is one of the common species responsible for an array of 
diseases in the respiratory tract, gastrointestinal tract, urinary tract, bones, joints 
and different systemic infections of normal and immunocompromised patients as 
well. It exhibits resistance to a wide variety of antimicrobial agents and expresses 
diverse molecular epidemiology to various established classes of antibiotics includ-
ing β-lactams, fluoroquinolones, tetracycline and aminoglycosides. Despite the 
low permeability, hydrophilicity and nonspecific behavior of the outer membrane 
to small molecular transport, it is inadequate to explain the degree of resistance in 
P. aeruginosa. The resistance mechanism of P. aeruginosa against various chemical 
agents is due to the complex chromosomally encoded genes. Different strains of 
P. aeruginosa having the inherent capacity for biofilm formation, further boosts the 
resistance under various environmental factors. This chapter explains pathogenic-
ity, mode and types of resistance of P. aeruginosa, its impact on the economy and 
available remediation/reduction measures and treatments.
Keywords: Pseudomonas aeruginosa, quorum sensing, adaptive resistance, acquired 
resistance, intrinsic resistance, efflux system
1. Introduction
Pseudomonas aeruginosa, a Gram-negative pathogen usually found in the 
hospital, plays a crucial role for nosocomial infection and are also responsible for 
acute and chronic infection. P. aeruginosa is ubiquitous in nature and shows a great 
 susceptibility against various classes of antibiotics [1]. The bacteria get colonize on 
any surface that contains water and multiply rapidly, carry out all the metabolic 
functions for growth and development which is an association of complex matrix 
known as a biofilm [2, 3]. The study predicted that a biofilm makes the bacteria more 
susceptible in the conditions like antibiotics, exposure in UV light and salinity [4]. 
Further understanding of the pathogenesis and resistance mechanism is a diverse 
area of investigation. Due to the complex biofilm forming ability, Pseudomonas 
species shows a great resistivity to various classes of antibiotics which are used to 
 persistently overcome the microbial infection. The occurrence of Pseudomonas  
species in the hospitals helps to form the biofilms on the medical instruments 
( surface only) and other similar devices along with the implants in the patients [5, 6]. 
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Pseudomonas species are used as a model organism for the study of biochemical 
mechanisms responsible for the susceptibility of the pathovars against a wide 
variety of antibiotics groups like amikacin, gentamicin, carbapenem, ofloxacin, 
ciprofloxacin, tigecycline, tobramycin and norfloxacin [7, 8].
The development of resistance by the pathogenic Pseudomonas species devise a 
major problem in the bacterial diversity by altering the genome sequences and the 
expression of proteins that ultimately improves the resistance of the pathovars  
[9, 10]. Various biochemical pathways and channel protein functions are affected 
due to the resistance of the bacteria [11, 12]. At this alarming stage of the scenario in 
details studies and prevention measures at an earliest is essential to control the same 
else in near future it may reach beyond our control. Therefore, the present chapter 
emphasizes on the infections due to Pseudomonas aeruginosa, their mechanism of 
infection and resistance to various classes of antibiotics.
2. Overview of Pseudomonas aeruginosa pathogenesis
The infectious diseases caused by P. aeruginosa are sometimes fatal for humans as 
it is a potential threat to people having less immunity like newborns, diseased per-
sons and veterans. Notably, patients suffering from the diseases like cystic fibrosis, 
urinary tract infection, burn of the skin, leukemia, HIV-AIDS, diabetes, patients 
having longer stay in hospital environments and persons having organ transplanta-
tion are highly susceptible to P. aeruginosa. Table 1 listed the disease, symptoms and 
its causes.
Disease caused in 
humans
Symptoms Adverse effects on human References
Bacteremia Fever, fatigue, chills, joint and 
muscle pain





Fever, chills, difficulty in 
breathing, cough with or 
without sputum production
Deposition of liquids in the 
parts of the lungs. Swelling and 
inflammation of the nasal tract
[14]
Folliculitis Abscess production in the 
skin, redness of the skin, 
draining wounds
Inflammation of the hair 
follicles by bacteria
[15, 16]
External ear canal 
Infection (otitis 
externa)
Ear pain, swelling, itching 
inside the ear, discharge from 
the ear, sometimes difficulty 
in hearing
Frequent showering leads to 
deposition of water and hence 
the growth of bacteria takes 





Redness, pain, swelling, 
inflammation, pus formation, 
impaired vision
The bacteria adhere to the lens 
and other parts of an eye within 
24 h of its exposure by its cilia 





Burning with urination, 
cloudy or bloody urine, 
strong odor, rectal pain (in 
male), pelvic pain (in female)
The transfer of bacteria into the 
urethra
[21]
Diabetic foot Swelling of foot and ankle, 
dry cracks in the skin(around 
the heel), corns or calluses
Tissue damage in the foot and 




Diseases and symptoms of Pseudomonas aeruginosa infection.
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The resistance of P. aeruginosa to different aminoglycoside agents show a 
tremendous threat to public health as well as constrains the therapeutic choice 
available. The use of multiple drugs against the diseases in a low dose make the P. 
aeruginosa strains more resistant to a wide range of antibiotics [23]. The different 
strains of P. aeruginosa showing resistance to various antibiotic classes along with 
the pathway of resistant have been demonstrated in Table 2.
3. Pathogenicity of Pseudomonas aeruginosa
The virulence property of P. aeruginosa is mainly due to the presence of factors 
like alkaline protease, elastase, pyoverdin, pyocyanin, exotoxins and cytotoxins. 
SI no. Strains of 
Pseudomonas 
aeruginosa
Showing resistance to 
antibiotic class
Mode of action References
1. PA40, PA43 Amikacin Multi-drug-resistance (MDR) [24, 25]
2. ATCC 27853, 
P2284
Ticarcillin/clavulanate Production of β-lactamase [26]





4. PA-M4 Ciprofloxacin Overexpression of MexEF-
OprN operon
[28]
5. OCR1 Gentamicin Overexpression of MexAB-
OprM operon
[28]
6. PAO4222 Carbapenem 
(imipenem and 
meropenem)
Loss of porin channels in the 
outer membrane, expression 








ribosomal methyl group 
transferase enzyme
[27]
8. PAO1 Tigecycline Inhibition of MexXY-OprM 
activity
[30]
9. KG3002 Ofloxacin Inactivation of MexC operon [31]
10. KG3000 Ciprofloxacin Expression of MexC-MexD-
OprJ operon
[32]
11. PAO1 Fluroquinolones DNA gyrase topoisomerase IV 
activity
[33, 34]
12. PA1109 Polymyxin E (colistin) Modification in the LPS layer [35, 36]
13. PA124 Tetracyclines Activation of MexXY-OprM 
efflux pump
[37]
14. PAO1 Quinolones Expression of MexEF-OprN 
efflux pump due to mutation 
of NfxB, NfxC and NalB
[38, 39]
15. ATTC 27853, 
K1178
Cephalosporin Overexpression of MexAB-




Antibiotics resistance in different strains of Pseudomonas aeruginosa.
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This virulence factors are commonly restricted to immunocompromised patients. 
The pathovars also produces a kind of exopolysaccharide known as alginate in 
patients having chronic respiratory infections. These alginate serves as the adhesive 
on the solid surfaces and also protects the bacteria from unfavorable environmental 
conditions [41]. The bacteria also produce alginate lyase enzyme which can cleave 
the polysaccharide into short oligosaccharide units it has been observed that both 
the biosynthesis and degradation process plays a vital role in the infection process 
[42, 43]. Presence of extracellular virulence factors and cell surface associated 
structures promotes its pathogenicity [44, 45].
P. aeruginosa binds to the ganglioside present in the host epithelial surface with 
the help of lipopolysaccharide and bacterial adhesins (i.e. type-IV pili and flagella). 
Type-IV also facilitates the bacterial movement along the host cell surface known 
as “twitching motility” which enhances the development of biofilm [46]. After the 
attachment to the host cell type III secretion system (T3SS) get activated and makes 
pore or a channel (i.e. translocon) on the cell membrane by injecting cytotoxic 
effector proteins into the cytosol of host cell [47, 48]. Mainly four different types of 
toxins are found in the P. aeruginosa sp. i.e. Exoenzymes S, T, U and Y. EXoS, ExoT 
and ExoU are responsible for N-terminal GTPase-activating proteinase (GAP) 
activity, C-terminal ADP-ribosyltransferase activity (ADPRT) and adenylate 
cyclase activity respectively [49]. It has been found that the ExoU is also a potent 
cytotoxin to cleave the host membrane phospholipid layers i.e. Phospholipase A2 
(PLA2) activity. The ExoU initiates the inflammation by secreting the arachidonic 
acid for activating lipoxygenase and cyclooxygenase pathways and results the 
production of prostaglandins. P. aeruginosa secretes an Exotoxin A which is a type 
of ADPRT that causes cell death by inhibiting protein synthesis due to suppression 
of host elongation factor 2(EF2) [50]. The lipase and phospholipase of the bacteria 
dissolve the surfactant lipids and phospholipids of the host cell membranes. The 
blue-green pigment pyocyanin develops the oxidative stress in host cells by disrupt-
ing the host catalase and electron transport system (ETS) hence suppresses the 
phagocytosis activity of the host immune system [51].
The type-VI secretion system (T6SS) seen in case of P. aeruginosa facilitates the 
interaction of this pathogen with other organism and provides defence from other 
bacteria. The H1-, H2- and H3-T6SS are the three distinct T6SS observed in this 
pathovars. The H1-T6SS is being used for the physiological study of antimicrobial 
activity [52, 53]. The H2- and H3-T6SS plays dual role in the interaction with both 
prokaryotic and eukaryotic cell. The production of proteases degrades the covered 
mucin and complement systems which results the disruption of the tight junctions 
between the host epithelial cells. Then the bacteria spreads from one cell to others 
by secreting the phospholipase by damaging the cell membrane [54]. The release 
of pyocyanin and pyoverdin interfere with the electron transport pathways and 
redox cycling system of the host cells. LasA and LasB are the two types of elastases 
produced by P. aeruginosa, commonly responsible for the burn wound infection and 
acute lung infections. The LasA hydrolyze the penta-glycine bridge necessary for 
the stabilization of the peptidoglycan in the cell wall and the LasB is responsible for 
the opsonisation of the lung surfactant proteins A and D [55].
4. Resistance for antimicrobials in Pseudomonas aeruginosa
A wide group of P. aeruginosa strains are resistance to various classes of anti-
biotics or antibacterial agents that makes it difficult to control the infection. The 
resistance in Pseudomonas species is broadly due to the below detail explained 
methods studied previously. Figure 1 explicitly elaborate on various mechanism of 
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P. aeruginosa resistance. The resistance pattern and mechanism behind the devel-
opment of resistance in the Pseudomonas species are the topic of interest for the 
researchers as it will help to develop the polyprophylactic procedures and mitigation 
of infection due to P. aeruginosa.
4.1 Enzymatic modification
P. aeruginosa consists of elements generally termed as transposons which induce 
resistance due to the modification of aminoglycoside enzymes. The infection due to 
the pathogen is usually combated by various class/groups of aminoglycoside antibi-
otics like kanamycin, gentamicin, streptomycin, amikacin and neomycin. Previous 
studies elucidate that, there are three types of enzymatic conformational change 
which are accountable for the resistance against the bactericidal compounds. These 
are phosphorylation of aminoglycoside phosphoryl transferase (APH) [56, 57]  
adenylation of aminoglycoside nucleotidyl transferase (ANT) and acetylation of 
aminoglycoside acetyl transferase (AAC) [58, 59].
The conformational modification and phosphorylation in the 3′-OH group is 
carried out by the APH enzyme. APH (3′) family of enzymes shows resistance 
against streptomycin, butirocin, amikacin, kanamycin and neomycin by encod-
ing the genes such as aphA and hpaA which are involved in the metabolism of 
4-hydroxy-phenylacetic acid (4-HPA). However, APH (2″) shows resistance to 
tobramycin and gentamycin classes of antibiotics. Due to adenylation of ANT 
enzymes P. aeruginosa increases resistance towards tobramycin, gentamicin, 
streptomycin, isepamicin and amikacin [60, 61]. The family of enzymes such as 
ANT (2″), (3″) and (4′) also shows a similar type of resistance in different strains 
of P. aeruginosa isolated from hospitals and intensive care unit (ICU) premises 
[62]. The N-terminal positions (1, 2′, 3 and 6′) of the (AAC) shows the enzy-
matic acetylation. Amongst various families, AAC (3-I), (3-II) and (3-III) are also 
resistant to gentamicin, tobramycin and kanamycin antibiotics respectively [63]. 
Apart from that AAC (6′) family of enzymes contributes to the resistance along 
with akamicin [64].
Figure 1. 
Resistance of P. aeruginosa to various antimicrobials as (1) shows the enzymatic modification,  
(2) impermeability resistance, (3) efflux system and (4) modification in the outer membrane.
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4.2 Impermeability resistance
Impermeability to various exocompounds in Gram-negative bacteria is due to 
lipopolysaccharide (LPS) present in the cell wall. LPS is made up of lipid A, oligo-
saccharide core and O antigen regions which are linked covalently [65]. The lipid 
A region is hydrophobic in nature and made up of a disaccharide of glucosamine 
which is phosphorylated and helps in the anchoring of LPS to the cell membrane. 
The core oligosaccharide is accumulation of sugar, ethanolamine, phosphate and 
amino acids and can be divided into inner and outer core. The O antigen is the outer 
domain of bacterial LPS made up of repeating glycan polymers and attached with 
the core region. It has been observed that the deletion of lipid A makes the bacteria 
susceptible to various classes of hydrophobic antibiotics and degradation of O side 
chains determine the smoothness and roughness of the LPS [66, 67]. The use of 
ethylenediaminetetraacetic acid (EDTA), some organic acids like lactic acid and 
citric acid are found to alter the impermeability of the Pseudomonas species. These 
chelating agents can neutralize the negatively charged oligosaccharide core by 
binding with the (Mg2+) cations in the LPS molecule and promotes the removal of 
LPS molecules [68]. The accumulation of aminoglycoside level decreases in the case 
of P. aeruginosa leading to low uptake and hence shows impermeability resistance 
which has been reported in the strains isolated from the cystic fibrosis patients [58]. 
Similarly, tobramycin resistance due to impermeability was seen when studied for 
endocarditis in case of rabbits.
4.3 Through the efflux system
The drug efflux system in bacteria includes three major components i.e. outer 
membrane channel-forming protein (OMF), resistance nodulation division (RND) 
which helps in drug-protein antiport process and the membrane fusion protein 
that acts as a periplasmic link between above two components [69]. The mexXY 
operon codes the inner membrane protein (i.e. MexY) and periplasmic protein (i.e. 
MexX). Resistance nodulation division (RND) involves the MexXY efflux system 
which develops the resistance in Pseudomonas species [70, 71]. MexAB-OprM shows 
resistance against ticarcillin, broad-spectrum cephalosporin and β-lactam of clinical 
isolates, while the combination of MexAB-OprM, MexCD-OprJ and MexXY-OprM 
shows the carbapenem resistance [72]. The bacterial isolates like Burkholderia 
pseudomallei and Escherichia coli involve the three component systems known as 
RND type aminoglycoside efflux system. Treatment with ofloxacin and gentamicin 
increases the level of MexXY expression in case of mutants compared to wild-type 
strains [73, 74]. The wild-type of strains of Pseudomonas is resistance to the anti-
biotic classes like tetracyclines, aminoglycosides, glycylcyclines and erythromycin 
but the MexXY can express in presence of diverse class of antibiotics like lincomycin 
[75], macrolides [76], fluoroquinolones [77], chloramphenicol [30], β-lactams 
[72], novobiocin [78] along with the wild type of antibiotic classes. In the reduced 
aminoglycosides condition both adaptive and impermeability resistance in the 
Pseudomonas sp. is expressed. The expression of MexXY gene is regulated by mexZ 
repressor, present in the upstream region of MexXY region of the gene and belongs 
to tetracycline repressor protein (TetR) and AcrR repressor protein family [79].
4.4 Modification in the outer membrane
The exoskeleton of the Gram-negative bacteria is present to resist against the 
adverse environmental conditions. Likewise, the outer membrane of P. aeruginosa 
is designed in such a way that it can permit small hydrophilic molecules and inhibit 
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larger molecules such as antibiotics [80]. Due to the crucial arrangement of aquaporin 
proteins in the cell membrane, the small hydrophilic antibiotics of quinolone and 
β-lactam classes can pass through the outer membrane. P. aeruginosa strains produce 
four major aquaporins (i.e. oprP, oprD, oprF and oprB) and two minor aquaporins 
(i.e. oprC, oprE) whereas the mutant strains lack oprF [81, 82]. The oprD is a 
specialized porin molecule present in bacterial membrane that helps in the process 
of up-taking positively charged amino acids like arginine and lysine [83]. The 
minimum inhibitory concentration increases due to the loss of oprD porin from the 
outer membrane of the Pseudomonas sp. thus increasing the resistance to imipenem 
class of antibiotics [84]. As the porin channels are impermeable to the polymyxin E 
and aminoglycoside, these molecules bind with the LPS present in the outer mem-
brane, destructs the barrier and allows the antibiotics to enter into the bacterial cells 
[85]. Through this mechanism the aminoglycosides can enter into the cytoplasm of 
the bacterial cell and disturb the protein synthesis process in the ribosomes that kills 
the bacteria simultaneously. But the overexpression of the oprH an outer membrane 
protein [86], prevents the binding of antibiotics to LPS making it resistant for 
laboratory strains of Pseudomonas species.
4.5 Resistance by biofilm
Bacterial communities aggregate themselves to a substratum and encapsulated 
in a proteinous polysaccharide of matrix evolved during adverse environmental 
condition such as various irradiation treatments and therapy which is known as 
biofilm. Mostly these polysaccharide/polymeric matrix leads to the formation of 
biofilms over a water surface and shows resistance and enhances their survivability 
against the antimicrobial agents [87, 88]. The formation of biofilm is predominantly 
found in case of various biomedical instruments such as catheter, implants, ventila-
tor and dialyser used patients residing in the hospital [89]. The bacteria are found 
to evade from host immune response due to the formation of biofilms and helps 
in promoting collateral damage to the tissues. Only few antibiotic classes act as an 
effective bactericidal agent for the free-floating bacteria but it fails to act against 
the bacteria forming biofilms as the biofilms are 1000 times more invulnerable 
to it [90, 91]. During environmental stress conditions, the bacteria change from 
free-living unicellular form to the planktonic form and then to the attached biofilm 
structure which enables the survivability of the bacteria. The matured biofilm starts 
to segregate from a place and develop an immobile structure in the new surfaces for 
colonization [92, 93]. The chemical therapy of antibiotics was not effective as the 
molecules cannot penetrate into the complex biofilm matrix due to the production 
of cover like exopolysaccharides matrix known as glycocalyx [94, 95]. Mostly the 
pathovars of P. aeruginosa forms the biofilm in the dialysis membrane and restricts 
the diffusion of piperacillin antibiotic into the complex aggregation [96]. It is 
pertinent to mention here that the bacterial biofilm is resistant to various classes/
groups of antibiotics.
4.6 Resistance by quorum sensing
The P. aeruginosa has been found to be resistive to various bactericidal agents and 
mainly infects to the people suffering from HIV-AIDS and cancer due to the com-
promised immune system, use of broad-spectrum antibiotics for a longer duration 
and dependency on life support medical devices like a catheter, ventilator and dialyser. 
The bacteria communicate with each other by secreting extracellular signaling mol-
ecules known as autoinducer. The autoinducer level is directly proportional to the 
growth of bacterial population, hence with the increase in bacterial population the 
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accumulation of autoinducer in the environment is at the peak [10, 97]. This process 
of production, release of signaling molecules is termed as quorum sensing.
There are four types of quorum sensing pathways discovered for the P. aeruginosa 
species which includes the LasR and LasI, RhlR and RhlI, PqsR-quinolone controlled 
system and the integrated quorum sensing (IQS) system which works under limiting 
conditions of phosphate [98, 99]. The formation of complexes of LasR with 3- 
oxo-C12-HSL activates the LasI synthase gene which helps in the process of autoin-
duction. The LasR complex regulates the expression of rhlI and rhlR genes along with 
the PQS systems which are related to the second and third mode of quorum sensing 
system of pathway respectively. The activation of its own regulon by the binding of 
C4-HSL with RhlR induces the second induction processes. The activation of RhlR 
is induced by PqsR-PQS complex which regulates the three modes of signaling in 
Quorum sensing along with inhibits the expression of the pqsR and pqsABCD. The 
ratio of 3-oxo-C12-HSL to C4-HSL gives an idea about the activation of PQS [100, 101]. 
The virulence property of P. aeruginosa is controlled by the RhlR along with C4-HSL 
and PqsR or LasR. Incase of the isolates of P. aeruginosa from the cystic fibrosis patients 
the mutations in the LasR supplies the autoinducer as there is the necessity of phos-
phate starvation protein (PhoB). This LasR activates the expression of pqs genes by the 
production of IQS which expresses the rhl gene hence shows the pathogenicity [102].
4.7 Others
Pseudomonas species also include the resistance mechanism like adaptive 
resistance, acquired resistance and intrinsic resistance which further helps in the 
increasing the resistivity of the pathogen to a wide range of antibiotic class.
4.7.1 Adaptive resistance
The resistance which is dependent on the physical and chemical stresses, growth 
states and promotes the initiation of the regular processes inside the cell in the 
presence of antibiotics and reverts back to the primary condition in the removal of 
the inducers are known as adaptive resistance [103, 104]. Previous research studies 
manifested that the resistance is due to many factors like the use of sub-inhibitory 
concentration of antimicrobial agents, polyamines, heat shock, SOS response, pH 
imbalance and anaerobiosis condition [105, 106]. P. aeruginosa was found to develop 
adaptive resistance against divalent Ca2+ and Mg2+ ions and the polymyxins which 
are controlled by PmrAB and PhoPQ pathways [107]. P. aeruginosa gradually reduces 
susceptibility in the presence of antibiotics and is altered in absentia this phenomena 
are reversible in nature and scientifically termed as the adaptive resistance [108]. 
The extensive studies revealed that adaptive resistance can also be developed in both 
in vivo and in vitro conditions due to the administration of antibiotics into the bacte-
rial culture for few hours and this resistance disappears after the removal of anti-
biotics from the media [109]. But it is observed that the organism shows resistance 
when there is a low accumulation of the aminoglycosides. The resistance induced 
through drug efflux system and due to the gene expression associated with anaerobic 
respiration. The bacteria were grown in the anaerobic condition and nitrate environ-
ment to check the accumulation and the uptake of aminoglycoside and found that  
P. aeruginosa is capable of showing resistance in the anaerobic conditions [110].
4.7.2 Acquired resistance
The acquired resistance involves the transfer of plasmids, prophages, DNA 
elements and transposons by means of transduction, transformation and 
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conjugation. This horizontal transfer shows the β-lactam and aminoglycoside 
resistance in P. aeruginosa [111]. The chemical modification of the aminoglyco-
sides alters the affinity of a 30S subunit of ribose sugar to the target. Antibiotic 
drugs like cephalosporin, carbapenem [112] and penicillin [113] help in the 
process of development of resistance property in case to P. aeruginosa [112]. The 
mutational resistance occurred due to the formation of biofilms and the action 
of DNA-damaging agents. The mutation frequency is found to be increased by 
10-fold, greater than 100-fold and 70-fold if the resistance is caused by merope-
nem [85], ciprofloxacin and if any mutation in genes respectively [114]. The 
downregulation of antioxidant enzymes damages the DNA in the biofilms. The 
library screening of cystic fibrosis (CF) patients describe that there are various 
mutators play a significant role during the early infection stages, mutL and mutS 
are the hypermutators which are widely found. The mutation in genes mexR, 
mexZ and nfxB is due to the overexpression of MexAB-OprM, MexXY-OprM and 
MexCD-OprJ efflux pump respectively. OprD is a porin that suppresses the uptake 
of imipenem [115] and another antibiotic [116] leading to the clinical resistance. 
The ampC β-lactamase, AmpD mutate and controls the activity of AmpR regula-
tor [117]. The P. aeruginosa clinical strain shows resistance to mutations in gyrase 
(gyrA) and gyrB as well as parC and parE. Overlay we can demonstrate that the 
mutations in the unrelated genes give rise to acquired resistance against different 
antibiotics.
4.7.3 Intrinsic resistance
The intrinsic resistance is due to the combination of the efflux system along 
with the β-lactamase and the low outer membrane permeability, the entry of 
antibiotic molecules through the outer membrane of the bacteria [8]. The increase 
in antibiotic concentration in the environment helps in the low permeability of the 
outer membrane permits the entry of larger compounds and antibiotics into the 
cell with the help of porin protein channels and makes the bacteria resistant this 
slow process helps in increased resistance of the organism [83, 118]. The intrinsic 
resistance is carried out by the help of multi-drug efflux systems like MexAB-OprM 
and MexXY-OprM operon along with the inactivation of enzyme β-lactams by 
hydrolysis [119, 120].
5. Impact of Pseudomonas aeruginosa on the economy
The low membrane permeability, overexpression of efflux pump and deletion of 
porin channels are the cause behind the resistance of Pseudomonas species. P. aeruginosa 
was predominantly found in the ICUs of European continents hence put in the list 
of “ESKAPE” pathogens by the Infectious Disease Society of America [121, 122]. 
The existing antibacterial agents are not effective against these isolates and hence a 
severe threat for public health. A study in China for the bacterial resistance surveil-
lance demonstrated that the resistance in case of hospital-acquired infection (HAI) 
is prevalence than community-acquired infection (CAI) [123]. Relatively few stud-
ies explained about the outbreak of Multi-drug resistance (MDR) in P. aeruginosa 
species. The worldwide study of Pseudomonas infections gives us the idea that in the 
year 2002 14% and in 2003 9.9% resistance were found in ICU isolates and nosoco-
mial infections in United states [77]. During 1997–1999 8.2% and 4.7% of resistance 
were due to nosocomial infections in South America and Europe respectively [124, 125]. 
In 2001 2.8% and in 2005 6.9% of resistance were due to nosocomial infections in Japan 
[126] and Malaysia [127].
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The National Nosocomial Infection Surveillance System (NNIS) also conducted 
the study for statistical analysis of the resistance developed by the hospital strains 
of P. aeruginosa and define that the hospital samples are more resistive to various 
groups of antibiotic classes [128]. The resistance to various classes of antibiotic by 
P. aeruginosa is a new threat to our defence system as once compromised it will be 
a difficult task to control the spread and infection of the bacteria among the living 
system. It has been also reported that the bacteraemia was not in control by the 
administration of antibiotics as it was spread by the antibiotic-resistant strains of  
P. aeruginosa [129].
Due to hospitalization for a significant period of time in the ICU [130] of a 
patient suffering from respiratory disorder [110], kidney disease [89] and other 
diseases which needs the ventilator along with the medical device installation are 
more prone to the infection of P. aeruginosa [131]. The administration of various 
drugs makes the Pseudomonas strain more resistive due to mechanisms like multi- 
drug-resistance (MDR), efflux systems, and loss of porin proteins from the outer 
membrane. Extensive research work is necessary to understand the infection mech-
anism and the development of resistance in the bacteria, the suitable combination 
of antibiotic molecules which will overcome the resistant behaviour and eradication 
of the bacterial biofilm without affecting the other processes in the living beings.
6. Mitigation of resistance
The eradication of the resistance is highly necessary for the prevention followed 
by cure to Pseudomonas infection for healthy sustenance. So, research is still going 
on to overcome the resistance by the organism and combinational therapeutic 
approach is found to be an effective tool against the resistance of the Pseudomonas 
species.
Cross-infection through hospital personnel gives rise to 30–40% of infection so 
irrespective of cost and time use of masks, cloths, gloves, antiseptics for the proper 
isolation can minimize the resistant developed in the pathovars [132]. It was observed 
that usual laboratory methods failed to detect the Antimicrobial-Drug resistance 
hence new testing methods, standards and guidelines implemented by various 
national and international clinical research groups for the early detection and control 
its outbreak [133]. The synergistic of two or more anti-bactericidal molecules is found 
to be an effective than monotherapy to overcome the resistance. The combination of 
polymixin with tobramycin is found to be an effective antimicrobial for inhibition 
in the formation of biofilms [134]. The combinational administration of tobramycin 
with aminoglycoside and macrolide clarithromycin shows a devastating effect against 
the biofilm [79]. Likewise, the integration of azithromycin with the tobramycin 
helped to destroy the bacterial biofilm when treated with in vitro condition [135].
The use of nitric oxide (NO) was reported to trigger the downstream of signal 
processing in quorum sensing and hence the production of cyclic-di-GMP decreases 
hence the extracellular matrix of biofilm get destroyed [136]. The introduction of 
deoxyribonuclease (DNAse) directly into the biofilm of the bacterial colony as it 
digests the environmental DNA (eDNA) enzymatically. The P. aeruginosa contains 
a molecule known as acyl-homoserine lactones (AHL), the blockage of signaling of 
this molecule prevents the formation of biofilms [137]. The rsaL gene expression acts 
as a negative regulator of the lasI gene expression which is responsible for the quo-
rum sensing in the strains of P. aeruginosa [138]. The PmrAB and PhoPQ can alter the 
permeability of the outer membrane as the level of divalent ions decrease it increase 
the extracellular DNA in the biofilms and shows resistance to cationic bactericidal 
peptides and polymyxins [139]. Due to this phenomenon, the addition of amino 
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arabinose to the 1st and 4th phosphate position in lipid A of the LPS and the net 
negative charge neutralized and the cations can enter into the bacterial cell [140].
The medical equipment and the biomaterial use for implantation purpose are 
coated with silver which reduces the adherence and biofilm producing ability of the 
bacteria. The novel compounds like curlicides and pilicides have been reported to 
inhibit the role of adhesin molecules and hence reduces the formation of biofilms 
on the surfaces. The use of nanomaterials of graphene and zinc as the coating of 
biomedical implants are found to be effective against the biofilm formation [141]. 
In some instances, it is necessary to replace the device after prolonged use with the 
patient/s. The small molecular artificially engineered peptide 1018 was discovered 
with the anti-biofilm activity [142].
The pharmaceutical industries are working towards the development of vaccines 
to tackle the antimicrobial resistance and few are under clinical trials which are 
believed to be effective against the resistance [143, 144]. There are several vaccines 
such as polysaccharide-protein conjugates, LPS-O antigen, OprI and OprF mem-
brane protein, live-attenuated, flagella and DNA vaccines are known to be invented 
for the control of antimicrobial resistance of P. aeruginosa. But the recombinant 
vaccine IC43, OprI and OprF and flagella vaccines are found effective and are under 
clinical trials for cystic fibrosis patients [145]. Apart from the above various NGOs 
and educational groups are playing a great role to educate the students, doctors, 
hospital personnel and society by making people aware about the use of proper dose 
and medicines by consulting the physician along with the maintenance of hygiene 
in the surroundings.
7. Concluding remarks
P. aeruginosa as an emerging human pathogen causes an array of diseases in 
immunocompromised patients, newborns as well as healthy persons. The infec-
tion as a biofilm is much more severe than monoculture. Various antimicrobial/
antibiotics treatment leads to not only increases the resistance in different strains 
of P. aeruginosa but also increase the disease incidence. The present chapter clearly 
enlightens various mechanisms of infection of P. aeruginosa, its biofilms and 
resistance pathways/mechanisms, global impact due to infections which further 
paves the way for various remediation in future through improved implementations 
of genetic engineering and advances nanotechnology tools.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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